ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1579

Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus  patients

Javier Merayo-Chalico1, Diana Gómez-Martín2, Roberta Demichelis-Gómez3, Sandra Rajme-Lopez2, Luis Aparicio-Vera2 and Jorge Alcocer-Varela2, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, 3Haematology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus, lymphopenia, risk assessment and thrombocytopenia

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease characterized by thrombocytopenia and microangiopathic hemolytic anemia and, in some cases, fever, neurologic and/or renal abnormalities. The mortality rate is high despite appropriate diagnosis and treatment. Presence of TTP in SLE is rare (< 2.5%) and diagnosis can be difficult between this two pathologies; sometimes, this results in delayed/suboptimal treatment with higher mortality. The aim of this study was to identify novel risk factors for TTP in SLE and to address the epidemiological profile in this subset of patients.

Methods:

We performed a retrospective, case-control study which included patients admitted between January 1994 and March 2013. Three different study groups were included as follows: Cases: TTP/SLE (A) and Controls: non-autoimmune TTP (B) and SLE without TTP (C). TTP was diagnosed by the presence of at least microangiopathic hemolytic anemia, thrombocytopenia < 100,000 cells/µl and high LDH levels. Variables that were measured included: demographic variables, SLEDAI score, clinical and laboratorial parameters (complete blood count, hemolytic parameters and serological tests), treatment, length of hospital stay and mortality. Differences between groups were analyzed by Student t test or U Mann-Whitney. Association between variables was assessed by OR (CI 95%). Multivariate analysis was performed by binary logistic regression model. 

Results:

Ninety one  patients were included: 23 in group A, 22 in group B and 46 in group C. Variables that were associated to TTP diagnosis in SLE patients in comparison to non autoimmune TTP were: lymphopenia (≤1000 cells/µl) (OR 11.5, CI 95% 2.82-47.35), severe anemia(≤7g/dl) (OR 4.9, CI 95% 1.03-7.32) and age (≤30 years) (OR 2.87, CI 95% 1.25-6.55), which remained significantly associated after multivariate analysis. Moreover, after comparing SLE patients with and without TTP, the variables that were related to TTP diagnosis included: severe thrombocytopenia (≤50,000 cells/µl) (OR 17.8, CI 95% 4.66-68.08), severe anemia (OR 8.07 CI 95% 2.33-27.9), history of hematological activity (OR 3.25 CI 95% 1.12-9.39), history of persistent thrombocytopenia (OR 3.21 CI 95% 1.002-10.31), positive antiphospholipid antibody profile (OR 3.11 CI 95% 1.083-8.93) and history of thrombosis (OR 1.20, CI 95% 1.048-1.37).  After the multivariate analysis, variables that remained significant were severe anemia (OR 8.9, CI 95% 1.81-43.8) and severe thrombocytopenia (OR 5.71, CI95% 1.5-21.7). Interestingly, we did not find differences in mortality between patients with TTP associated to SLE and non autoimmune TTP.

Conclusion:

Patients with TTP associated with SLE are younger than non-autoimmune TTP. Severe anemia, severe thrombocytopenia and lymphopenia are independent risk factors for TTP in SLE. These findings might lead to early diagnosis and treatment as well as lower mortality.


Disclosure:

J. Merayo-Chalico,
None;

D. Gómez-Martín,
None;

R. Demichelis-Gómez,
None;

S. Rajme-Lopez,
None;

L. Aparicio-Vera,
None;

J. Alcocer-Varela,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-risk-factors-for-thrombotic-thrombocytopenic-purpura-in-systemic-lupus-erythematosus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology